Emil D Kakkis bought RARE once, on Sep 11, 2019

Emil D. Kakkis, M.D., Ph.D. is the Founder, President, and Chief Executive Officer of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases.( He founded Ultragenyx in 2010 with a patient-centric approach to drug development, challenging traditional clinical protocols and commercialization models; under his leadership, the company has grown to over 1,200 employees, achieved four approved therapies for five rare diseases, and generated nearly $300 million in annual revenue by recent reports.(

Kakkis began his career at Harbor-UCLA Medical Center, developing enzyme replacement therapy for MPS I, and joined BioMarin in 1998, where he led approvals for three rare disease treatments (MPS I, MPS VI, PKU) and initiated programs for others.( A board-certified pediatrician and medical geneticist, he graduated magna cum laude from Pomona College with the Vaile Prize in Biology and earned combined M.D. and Ph.D. degrees from UCLA, receiving the Bogen Prize; he completed residency and fellowship at Harbor-UCLA.( Kakkis founded the EveryLife Foundation for Rare Diseases to advocate for policy improvements and has received awards including the California Life Sciences Pantheon award, Lifetime Achievement from the National MPS Society, and BIO’s Henri Termeer Visionary Leadership award.(

Written by Perplexity from public sources.